3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof

A compound, or a pharmaceutically acceptable salt thereof, of Formula I:

• wherein:
• R1 is selected from the group consisting of -heteroaryl(R4)q and -heterocyclyl(R5)h;
• R2 is selected from the group consisting of H and halide;
• R3 is selected from the group consisting of H, -heteroaryl(R6)q, -heterocyclyl(R7)h, and -aryl(R8)k;
• each R4 is one substituent attached to the heteroaryl and is independently selected from the group consisting of halide, —(C1-6alkyl), —(C1-4alkylene)pheterocyclyl(R9)h, —(C1-4alkylene)pcarbocyclyl(R10)j, —(C1-4alkylene)paryl(R11)k, —NHC(═O)R12, —NR13R14, —(C1-6alkylene)NR15R16, and —OR22;
• each R5 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• each R6 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-6alkyl), halide, —CF3, —OCH3, —CN, and —C(═O)R17;
• each R7 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-6 alkyl), halide, —CF3, —CN, and —OCH3;
• each R8 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-6alkyl), halide, —CF3, —CN, —OCH3, —(C1-6 alkylene)pNHSO2R17, —NR13(C1-6 alkylene)NR13R14, —(C1-6 alkylene)pNR13R14, and —OR25;
• each R9 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of amino, —(C1-4 alkyl), halide, —CF3, and —CN;
• each R10 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• each R11 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• each R12 is independently selected from the group consisting of —(C1-9 alkyl), -heteroaryl(R18)q, -aryl(R19)k, —CH2aryl(R19)k, -carbocyclyl(R20)j, —CH2carbocyclyl(R20)j, —(C1-4 alkylene)pNR23R24, - heterocyclyl(R21)h, and —CH2heterocyclyl(R21)h;
• each R13 is independently selected from the group consisting of H and —(C1-6 alkyl);
• each R14 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j;
• each R15 is independently selected from the group consisting of H and —(C1-6 alkyl);
• each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —CH2aryl(R19)k, and —CH2carbocyclyl(R20)j;
• each R17 is a —(C1-6 alkyl);
• each R18 is one substituent attached to the heteroaryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• each R19 is one substituent attached to the aryl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• each R20 is one substituent attached to the carbocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• each R21 is one substituent attached to the heterocyclyl and is independently selected from the group consisting of —(C1-4 alkyl), halide, —CF3, and —CN;
• R22 is selected from the group consisting of H, —(C1-6alkyl), —(C1-4alkylene)pheterocyclyl(R21)h, —(C1-4alkylene)pcarbocyclyl(R20)j, —(C1-4alkylene)paryl(R19)k, and —(C1-6alkylene)pNR23R24;
• each R23 is independently selected from the group consisting of H and —(C1-6 alkyl);
• each R24 is independently selected from the group consisting of H and —(C1-6 alkyl);
• R25 is selected from the group consisting of H, —(C1-6 alkyl), —(C1-4 alkylene)pheterocyclyl(R21)h, and —(C1-6 alkylene)pNR23R24;
• each p is independently 0 or 1;
• each q is independently 0 to 4;
• each h is independently 0 to 10;
• each k is independently 0 to 5;
• and
• each j is independently 0 to 12.